Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is engaged as a specialized men’s health company, which is focused on the research, development, acquisition, and commercialization of treatments for health issues such as erectile dysfunction, Peyronie’s disease, hormone health, substance abuse disorders, and more.
Shares of the men’s health company are soaring 92% through early trading on Wednesday, November 3, 2021. Over the past three months, Petros Pharmaceuticals has seen average daily volume of 94,460 shares. However, volume of 87.33 million shares or dollar volume of $273.34 million, has already exchanged hands through early trading Wednesday.
The men’s health company is seeing its share price rally after disclosing sales of its STENDRA treatment has surged 476% year-over-year, thanks to an exclusive digital health marketing agreement with telehealth platform, Hims & Hers Health, Inc. (NYSE: HIMS).
STENDRA is an FDA-approved erectile dysfunction medication that is available in 50mg, 100mg, and 200mg tablets. Patients can obtain STENDRA tablets now through the Hims platform. Upon sign up and a virtual consultation with a licensed healthcare provider approving the treatment, patients can access the treatment.
“Our continued relationship with Hims supports an industry-leading telehealth platform that allows individuals to inquire about and address erectile dysfunction with discretion and by way of a convenient method of healthcare engagement,” said Fady Boctor, Petros Pharmaceuticals’ President and Chief Commercial Officer. “With significant growth year-over-year of STENDRA tablet sales through Hims, we are excited to expand our collaboration with Hims and enhance access to STENDRA through this critical channel.”
Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.